第一医药(600833) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 330,419,187.40, a decline of 34.19% compared to CNY 502,080,000.94 in the same period last year[8] - Net profit attributable to shareholders decreased by 46.07% to CNY 10,052,516.76 from CNY 18,638,693.76 year-on-year[8] - Basic and diluted earnings per share fell by 45.99% to CNY 0.0451 from CNY 0.0835 in the same period last year[8] - Total operating revenue for Q1 2021 was ¥330,419,187.40, a decrease of 34.2% compared to ¥502,080,000.94 in Q1 2020[20] - Net profit for Q1 2021 was ¥10,052,516.76, a decline of 46.1% from ¥18,638,693.76 in Q1 2020[20] - Earnings per share for Q1 2021 were ¥0.0451, compared to ¥0.0835 in Q1 2020, reflecting a decrease of 46%[20] - The company reported a comprehensive income total of ¥91,548.74 for Q1 2021, compared to ¥13,902,501.82 in Q1 2020[20] - The company experienced a tax expense of ¥4,698,974.05 in Q1 2021, down from ¥5,915,445.41 in Q1 2020[20] - Other comprehensive income after tax for Q1 2021 was -¥9,960,968.02, compared to -¥4,736,191.94 in Q1 2020[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 139.27%, reaching CNY 16,462,872.11 compared to a negative CNY 41,922,771.04 in the previous year[8] - Cash flow from operating activities was ¥16,462,872.11, a significant improvement of 139.27% year-on-year[12] - The net cash flow from operating activities for Q1 2021 was ¥1,661,715.57, a significant improvement compared to a net outflow of ¥86,421,552.25 in Q1 2020[25] - Total cash inflow from operating activities decreased to ¥132,812,941.56 in Q1 2021, down 27.6% from ¥183,565,555.03 in Q1 2020[25] - Cash outflow from operating activities also decreased to ¥131,151,225.99 in Q1 2021, down 51.4% from ¥269,987,107.28 in Q1 2020[25] - The company reported a net cash flow from investing activities of -¥1,399,387.46 in Q1 2021, an improvement from -¥3,919,963.22 in Q1 2020[25] - Cash flow from financing activities showed a net outflow of -¥181,945,227.22 in Q1 2021, compared to a net inflow of ¥179,779,444.44 in Q1 2020[25] - The ending cash and cash equivalents balance decreased to ¥319,713,293.01 in Q1 2021 from ¥506,282,377.80 in Q1 2020, representing a decline of 37%[25] Assets and Liabilities - Total assets decreased by 10.83% from the end of the previous year to CNY 1,245,084,076.08[8] - Total current assets decreased to ¥672,459,207.70 from ¥879,352,653.92, reflecting a decline of approximately 23.5%[14] - Total liabilities decreased to ¥498,215,275.47 from ¥646,939,073.40, a reduction of about 23%[15] - Cash and cash equivalents dropped to ¥332,376,819.77 from ¥509,431,257.61, a decrease of approximately 34.7%[14] - Inventory decreased to ¥203,119,619.63 from ¥215,578,597.09, a decline of about 5.8%[14] - Total non-current assets increased to ¥572,624,868.38 from ¥516,903,138.23, an increase of approximately 10.8%[14] - Total liabilities as of Q1 2021 amounted to ¥518,025,866.39, down from ¥689,514,114.21 in the previous year[18] - The company's total equity as of January 1, 2021, was ¥746,777,251.87, a decrease of ¥2,539,466.88 from the previous year[29] Financial Management - The company’s financial expenses decreased by 76.26%, resulting in a net financial income of CNY -6,772,371.29[11] - The company fully repaid short-term loans during the reporting period[12] - The company reported a tax expense of CNY 3.40 million for Q1 2021, up from CNY 2.05 million in Q1 2020[22] - The financial expenses for Q1 2021 included interest expenses of ¥757,660.19, an increase from ¥220,555.56 in Q1 2020[20] - Sales expenses decreased significantly to CNY 957,316.52 from CNY 8.15 million in Q1 2020, reflecting cost control measures[22] Future Outlook - The company has not indicated any significant changes in net profit forecasts for the upcoming reporting period[12] - The company plans to focus on market expansion and new product development as part of its future strategy[22]